pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,276 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1571Endpoints1231BioSpace570Fierce Biotech564BioPharma Dive467raps194onclive165fda recalls
therapy area
allOncology10490Rare Disease2769Immunology2472Cardiology2292Hematology1893Pulmonology1881Vaccines
  • Exercise and echocardiograms helped keep astronauts’ hearts stable during six-month spaceflight, study finds
    A team of international researchers examined 13 astronauts who spent six months aboard the International Space Station. The crew underwent regular onboard echocardiograms to monitor heart size and…
    STAT · 1mo agoPositive readoutPositive↗ source
  • Legend Biotech appoints former Novartis executive as CEO while Vera pursues full approval for kidney drug
    Legend Biotech announced that Ingrid Zhang, a former Novartis executive, will take over as chief executive officer, replacing Ying Huang who stepped down in July. Vera reported that its recently l…
    STAT · 1mo agoNeutral↗ source
← prev
page 19 of 92
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology877
Endocrinology & Metabolism691
Pain657
Nephrology654
  • STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
    GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China
    STAT · 1mo agoDealNeutral↗ source
  • NIH now allows businesses to apply for its research funding
    The National Institutes of Health announced that companies are eligible to submit grant applications, expanding the pool of potential research partners. This change aims to foster collaboration bet…
    STAT · 1mo agoRegulatoryPositive↗ source
  • States urged to apply tobacco-settlement lessons to Meta’s $18 billion payout
    Susan Morrisey, former head of Colorado’s tobacco‑control coalition, reflects on how the 1998 tobacco settlement was debated and allocated among competing interests in the state. She recalls that…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • RFK Jr. to keynote Children’s Health Defense event as hospitals criticize GOP rural health fund
    Robert F. Kennedy Jr. is slated to deliver the keynote address at a Children’s Health Defense gathering, marking a return to the anti-vaccine activism that defined his recent public profile. Hospi…
    STAT · 1mo agoNeutral↗ source
  • Summit and Akeso report ivonescimab extends lung cancer survival by eight months versus Keytruda in Phase 3 trial
    Summit Therapeutics and its partner Akeso said their experimental dual-target drug ivonescimab added about eight months of overall survival for patients with lung cancer compared with Merck's Keytr…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • AstraZeneca’s newly approved pill fails frontline breast cancer study
    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
    BioPharma Dive · 1mo agoApprovalPositive↗ source
  • FDA approves Scholar Rock's muscle-targeted SMA therapy Isembyld
    The Food and Drug Administration has approved a new medication for spinal muscular atrophy (SMA). The drug, apitegromab marketed as Isembyld, is the first muscle-targeted therapy for the disease.…
    BioPharma Dive · 1mo agoApprovalPositive↗ source
  • Judge blocks Trump administration's plan to cap visas for grad students and postdocs
    A federal judge issued a preliminary injunction on Monday, stopping the Trump administration's plan to limit the length of visas used by graduate students and postdoctoral researchers. The Departm…
    STAT · 1mo agoRegulatoryPositive↗ source
  • Abbott to pay $385 million to settle claims over 2022 baby-formula plant shutdown
    Abbott Laboratories agreed to a $385 million settlement related to the 2022 shutdown of its Sturgis, Michigan baby-formula plant, the largest in the United States. The plant’s problems triggered a…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Cellectis abandons CAR-T programs, shifts focus to in vivo gene editing
    Cellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines. The company said the commercial and clinical landscape for…
    BioPharma Dive · 1mo agoNegative↗ source
  • GSK presents promising late-stage lung cancer data from two investigational drugs
    GSK highlighted late-stage results for two of its lung cancer candidates, reporting encouraging efficacy signals that could advance the programs toward regulatory review. The company shared the da…
    STAT · 1mo agoPositive readoutNeutral↗ source
  • AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trial
    AstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease…
    STAT · 1mo agoNegative readoutNegative↗ source
  • Definium’s LSD therapy cuts anxiety scores in second late-stage trial
    Definium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…
    STAT · 1mo agoPositive readoutPositive↗ source
  • Pennsylvania reports third measles death this year, a 40-year-old woman in Jefferson County
    Pennsylvania officials confirmed a third measles-related death in the state this year, involving a 40-year-old woman in Jefferson County. Coroner Greg Furlong said the death was measles-related bu…
    STAT · 1mo agoNegative↗ source
  • Third measles-related death reported in Pennsylvania amid ongoing outbreak
    A 40-year-old woman in Pennsylvania died from complications related to measles, marking the third measles-related fatality in the state in recent weeks. The death was confirmed by Jefferson County…
    STAT · 1mo agoNegative↗ source
  • Novo Nordisk rebrands as "Novo" to signal renewed focus amid slipping market share
    Novo Nordisk announced it will drop "Nordisk" from its name, adopting the shorter brand "Novo" along with a new slogan "Lasting Health Starts Now" as part of a cultural shift. The company says the…
    STAT · 1mo agoNegative↗ source
  • Hospital leaders say GOP's $50 billion rural health fund falls far short of Medicaid cuts
    Republican lawmakers added a $50 billion Rural Health Transformation Fund to the tax‑cut legislation, aiming to help hospitals cope with planned Medicaid cuts. The fund represents only about 5 % o…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Republicans push $500 cash checks for ACA enrollees, highlighting cash-first health policy and GLP-1 drug surge
    Bob Herman’s STAT+ newsletter examines how the Trump administration is issuing $500 checks to a narrow group of Affordable Care Act participants just before the midterm elections. The move reflects…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Opinion: Restoring public trust in science requires humility and collaboration, not just better messaging
    Michelle Groman and Caroline Montojo, presidents of The Greenwall Foundation and the Dana Foundation, wrote an opinion piece on Sept. 14, 2026 about the challenge of rebuilding public trust in scie…
    STAT · 1mo agoNeutral↗ source
  • Robert F. Kennedy Jr. to keynote at Children’s Health Defense conference, returning to group he once led
    Health Secretary Robert F. Kennedy Jr. will deliver a keynote address at a conference hosted by Children’s Health Defense, the anti‑vaccine nonprofit he previously led. Kennedy joined the organiza…
    STAT · 1mo agoNeutral↗ source
  • Football fan wrestles with love for the game amid rising CTE concerns
    Michael Arkush, a sportswriter and New York Giants fan, reflects on his excitement for the 2026 season while confronting the growing awareness of chronic traumatic encephalopathy (CTE) in football.…
    STAT · 1mo agoNeutral↗ source
  • Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%
    A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation"…
    STAT · 1mo agoRegulatoryNegative↗ source
  • AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trial
    AstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…
    STAT · 1mo agoNegative readoutNegative↗ source